摘要
目的:探讨复方脑肽节苷脂注射液对急性脑梗死的临床疗效及对脂蛋白相关磷脂酶(Lp-PL)A2、超敏C反应蛋白(hs-CRP)、神经元特异性烯醇化酶(NSE)水平的影响。方法:选取2017年1月至2018年6月在我院住院治疗的急性脑梗死患者160例,随机分为对照组和治疗组,各80例。两组患者均按2018年中国急性缺血性卒中治疗指南进行基础治疗,在此治疗的基础上治疗组加用复方脑肽节苷脂注射液治疗,疗程2周,并随访3个月,比较两组患者治疗前后及随访3个月后的神经功能缺损评分(NIHSS)、日常生活能力量表(ADL)评分,检测两组患者治疗前后的Lp-PLA2、hs-CRP、NSE水平变化,比较两组患者治疗前后不良反应发生情况。结果:治疗后与治疗前相比,两组患者的NIHSS评分明显下降、ADL明显升高,两组患者的Lp-PLA2、hs-CRP、NSE水平明显下降,差异具有统计学意义(P<0.05);且治疗组在治疗后NIHSS评分较对照组显著下降、ADL较对照组显著升高,治疗组Lp-PLA2、hs-CRP、NSE水平显著低于对照组,差异具有统计学意义(P<0.05);两组患者间不良反应发生情况无明显差异(P>0.05)。结论:应用复方脑肽节苷脂注射液能有效改善神经功能缺损症状况,改善患者生活质量,显著降低急性脑梗死患者Lp-PLA2、hs-CRP、NSE水平,未增加不良反应的发生,复方脑肽节苷脂注射液值得临床上进一步推广治疗。
Objective:To investigate the clinical effect of compound cerebral peptide glycoside injection on acute cerebral infarction and its effect on lipoprotein related phospholipase(LP-PL)A2,hypersensitive C reactive protein(hs-CRP)and neuron-specific enolase(NSE)levels.Methods:160 patients with acute cerebral infarction hospitalized in our hospital from January 2017 to June 2018 were randomly divided into control group and treatment group,80 cases each.All the patients were treated according to"2018 Chinese guidelines for the treatment of acute ischemic stroke".Moreover,patients in the treatment group were given compound cerebral peptide glycoside injection for two weeks.All the patients were followed for 3 months.The NIHSS and ADL scores were evaluated before and after treatment and 3 months follow-up between two groups.Furthermore,the changes of Lp-PLA2,hs-CRP and NSE levels before and after treatment were detected in the two groups,and the occurrence of adverse reactions before and after treatment were compared in the two groups.Results:The NIHSS score and ADL of patients were significantly decreased in the two groups,and the levels of Lp-PLA2,hs-CRP and NSE were significantly decreased in the two groups when after treatment compared with before treatment,with statistically significant differences(P<0.05);After treatment,NIHSS score in the treatment group was significantly decreased and ADL was significantly increased compared with the control group.The levels of Lp-PLA2,hs-CRP and NSE in the treatment group were obviously lower than those in the control group,with statistically significant differences(P<0.05);There was no significant difference in the occurrence of adverse reactions between the two groups(P>0.05).Conclusion:The application of compound cerebral peptide glycoside injection can effectively improve the condition of neurological dysfunction and the quality of life of patients,significantly reduce the levels of Lp-PLA2,hs-CRP and NSE in patients with acute cerebral infarction,and do not increase the occu
作者
李兴明
刘娟娟
陈俊斌
刘建祥
焦臣泽
LI Xingming;LIU Juanjuan;CHEN Junbin(Yuebei People's Hospital Affiliated to Shantou University Medical College,Guangdong Shaoguan 512026,China)
出处
《河北医学》
CAS
2020年第3期393-397,共5页
Hebei Medicine
基金
2014年韶关市科技计划医学项目，(编号:2014CX/K207)
2010年韶关市科技计划医学项目，(编号:韶科(卫)2010-23)
2017年度韶关市卫生计生科研项目，(编号:Y17022)
关键词
急性脑梗死
复方脑肽节苷脂注射液
临床疗效
Acute cerebral infarction
Compound cerebral peptide glycoside injection
Clinical efficacy
